Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jemermed.2010.11.058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.
Ther Adv Drug Saf
January 2025
Department of Pharmacy, Daping Hospital, Army Medical University, No. 10 Changjiang Branch Road, Yuzhong District, Chongqing 400042, China.
Background: Gilteritinib and midostaurin are FLT3 inhibitors that have made significant progress in the treatment of acute myeloid leukemia. However, their real-world safety profile in a large sample population is incomplete.
Objectives: We aimed to provide a pharmacovigilance study of the adverse events (AEs) associated with gilteritinib and midostaurin through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.
Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature.
Cureus
December 2024
Subir Chowdhury School of Quality and Reliability, Indian Institute of Technology, Kharagpur, IND.
Article Synopsis
- Zolbetuximab is a chimeric monoclonal antibody designed to target the Claudin 18.2 protein, which is overexpressed in certain gastrointestinal cancers, notably gastric and gastroesophageal junction adenocarcinomas.
- This drug initiates an immune response to attack cancer cells when combined with standard chemotherapy regimens, and it has been approved as a first-line treatment for advanced, unresectable cancers in specific patient populations.
- Clinical trials show that zolbetuximab significantly improves progression-free survival and overall survival rates compared to chemotherapy alone, while maintaining a relatively safe profile for patients.
Broadening the conceptualization of panic disorder to include the fear presentation of avoidant/restrictive food intake disorder: The legacy of panic control therapy.
Behav Res Ther
December 2024
Rogers Behavioral Health, Research Center, Oconomowoc WI & Philadelphia PA, 34700 Valley Rd, Oconomowoc, WI, 53066, USA. Electronic address:
The presentation of avoidant/restrictive food intake disorder (ARFID) characterized by fear of aversive consequences of eating (fear-ARFID) has both phenomenological and mechanistic similarities to panic disorder. In this narrative review, we propose a shared model of the pathogenesis of the two disorders, centered on interoceptive sensitivity as the key maintenance mechanism. We review the evidence that fear-ARFID, which involves restrictive eating motivated by a desire to avoid aversive events (e.
View Article and Find Full Text PDFEVIDENCE FOR ADRENAL DYSFUNCTION CONTRIBUTING TO PERACUTE MORTALITY SYNDROME IN RED PANDA ().
J Zoo Wildl Med
December 2024
Zoological Pathology Program, Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Brookfield, IL 60513, USA.
Red pandas () are endangered with extinction due to deforestation and habitat fragmentation. Reported causes of unexpected death in managed red pandas include kidney, liver, gastrointestinal, and cardiac disease. A previously undetailed syndrome, red panda peracute mortality syndrome, may be emerging, as red pandas have died unexpectedly, with no clear cause of death identified at necropsy.
View Article and Find Full Text PDFA real-world disproportionality analysis of tirzepatide-related adverse events based on the FDA Adverse Event Reporting System (FAERS) database.
Endocr J
November 2024
Department of Pharmacy, Zhangjiagang TCM Hospital, Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu 215600, China.
Article Synopsis
- Tirzepatide is a new drug for treating type 2 diabetes and controlling weight, but there's a need to investigate its safety.
- The study utilized the FDA's FAERS database to analyze adverse events (AEs) related to tirzepatide between Q2 2022 and Q4 2023, identifying 8,096 reported AEs from a total of 638,153.
- The analysis revealed 98 positive signals for AEs linked to tirzepatide, with common expected AEs like nausea and injection site pain, and unexpected AEs including incorrect dosages and increased blood glucose, highlighting the importance of ongoing safety assessments for new medications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!